SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Pediatrix Medical Group, Inc. – ‘8-K’ for 9/19/22

On:  Friday, 9/23/22, at 4:31pm ET   ·   For:  9/19/22   ·   Accession #:  1193125-22-250187   ·   File #:  1-12111

Previous ‘8-K’:  ‘8-K’ on / for 8/4/22   ·   Next:  ‘8-K’ on / for 11/3/22   ·   Latest:  ‘8-K’ on 4/25/24 for 4/19/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/23/22  Pediatrix Medical Group, Inc.     8-K:5       9/19/22   10:133K                                   Donnelley … Solutions/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     23K 
 5: R1          Document and Entity Information                     HTML     45K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- d319654d8k_htm                      XML     13K 
 7: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 3: EX-101.LAB  XBRL Labels -- md-20220919_lab                       XML     53K 
 4: EX-101.PRE  XBRL Presentations -- md-20220919_pre                XML     33K 
 2: EX-101.SCH  XBRL Schema -- md-20220919                           XSD     12K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    18K 
10: ZIP         XBRL Zipped Folder -- 0001193125-22-250187-xbrl      Zip     11K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX: 
  Form 8-K  
 i false  i 0000893949 0000893949 2022-09-19 2022-09-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM  i 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported):  i September 19, 2022

 

 

 i Pediatrix Medical Group, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

 i Florida    i 001-12111    i 26-3667538

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 i 1301 Concord Terrace

 i Sunrise,  i Florida

   i 33323
(Address of principal executive office)   (zip code)

Registrant’s telephone number, including area code:  i (954)  i 384-0175

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 i 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 i 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 i 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 i 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

 i Common Stock, par value $.01 per share    i MD    i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  i 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 19, 2022, Pediatrix Medical Group, Inc., a Florida corporation (the “Company”), announced that Dominic J. Andreano, the Company’s Executive Vice President, General Counsel and Secretary, would transition from such position, effective on or about October 14, 2022 (the “Effective Date”). Mr. Andreano’s transition from his role as Executive Vice President, General Counsel and Secretary of the Company is a termination without “Cause” pursuant to that certain Amended and Restated Employment Agreement, effective September 27, 2020, by and between Mr. Andreano and a wholly-owned subsidiary of the Company, and Mr. Andreano will receive the benefits thereunder following the execution of a general release of claims in favor of the Company. The Company and Mr. Andreano intend to enter into a consulting agreement pursuant to which Mr. Andreano will continue to serve as an advisor to the Company following the Effective Date. Ms. Mary Ann Moore, the Company’s Executive Vice President, Chief Enterprise Risk and Legal Operations Officer, will be appointed the Company’s Executive Vice President, General Counsel and Secretary upon Mr. Andreano’s transition from his current role.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Pediatrix Medical Group, Inc.
Date: September 23, 2022     By:  

/s/ C. Marc Richards

     

C. Marc Richards

Chief Financial Officer


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
10/14/22
Filed on:9/23/22
For Period end:9/19/22
9/27/203,  8-K
 List all Filings 
Top
Filing Submission 0001193125-22-250187   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Apr. 26, 8:43:04.1pm ET